Search fresh public links, source activity, and ready-to-use post angles for Evolus Inc.
Fresh curated links around Evolus Inc are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The licensing and distribution agreement expands the company's injectable portfolio into the skin quality category.
The company is building a dedicated sales and medical affairs team to drive adoption of its neurotoxin and provide practices with direct clinical and commercial support.
An Evolv Technologies director exercised vested options at $0.24 per share and immediately liquidated them at $5.94.
Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead mov...
Eighth partnership of 2026 brings the entrepreneur-owned alternative to private equity to Northeast Ohio CHICAGO, July 21, 2026 /PRNewswire-PRWeb/ -- Aviva Aesthetics, the nation's...
Attovia Therapeutics has filed for an IPO to secure funding for assets, including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.
Establishment Labs is poised to get a boost from widening GLP-1 use as it is set to expand its breast implant business in the U.S., per TD Securities.
The treatment is the first short-duration facial injectable available in the region for the temporary improvement of lines between the eyebrows.
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
Elevance Health is kicking off another round of quarterly earnings results for major insurers, posting $1.5 billion in profit for Q2.
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor lande...
Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery e...
Eligible stockholders may elect to receive the dividend in cash or additional shares, with August 31, 2026 set as the record date. EvonSys today announced the declaration of a divi...
Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.